Update: Cell Therapy Biotech Raises €47M to Fund NASH Clinical Trial
Update (17/12/2019): Promethera has increased the total raised in its Series D round to €47.2M…
Update (17/12/2019): Promethera has increased the total raised in its Series D round to €47.2M…
A stem cell therapy developed by the Belgian company Promethera has improved symptoms, such as…
Experts say hemophilia treatment is at a 'precipice of a therapeutic revolution.' From antibodies to…
When the Japanese researcher Shinya Yamanaka managed to reprogram adult cells into an embryonic-like state…
Since 2014, investment in Non-Alcoholic SteatoHepatitis (NASH) has taken off with a fervor reminiscent of…
Promethera is collecting cash to fuel its liver disease program that revolves around HepaStem. I…
Which part of our body do European biotechs prefer to target? And how diversified are…
Artificial three-dimensional tissues to regenerate bones and soft tissues: Novadip Biosciences’ dream is a step…
Promethera Biosciences, a Belgian biotechnology company developing Promethera HepaStem, a cell-based therapy for the treatment…
Promethera is a promising Belgian Biotechnology company developing stem-cell based treatment against liver diseases. It…